Protelis Biotech
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Institute, hospital research
Protelis Biotech is a Philadelphia-based biotechnology company dedicated to developing modular, VHH-based multispecific biologics for precision immunotherapy. In addition to our internal programs, Protelis serves as a strategic advisor to the Technology Licensing Office at Thomas Jefferson University.
We are currently raising seed capital for two ventures:
- $5M for Protelis Bio to advance a first-in-class anti-CD147/VEGF biologic for Diabetic Retinopathy and Age-related Macular Degeneration (AMD).
- $2M for Cimbra Therapeutics to progress a first-in-class SIGMA-1 inhibitor for the treatment of Prostate Cancer.
We welcome interest from venture investors and pharmaceutical partners to learn more about:
- Protelis Bio
- Cimbra Therapeutics
- Innovative technologies emerging from Thomas Jefferson University
Let’s connect to explore partnership opportunities.
Address
PenningtonUnited States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}